Altrinsic Global Advisors’s Nektar Therapeutics NKTR Stock Holding History

Altrinsic Global Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-30,667	Closed	-$5.75M	–	87
2015 Q2	$5.75M	Hold	30,667	–	–	0.12%	64
2015 Q1	$5.06M	Hold	30,667	–	–	0.11%	61
2014 Q4	$7.13M	Hold	30,667	–	–	0.15%	55
2014 Q3	$5.55M	Sell	30,667 -1,333	-4%	-$255K	0.11%	57
2014 Q2	$6.15M	Hold	32,000	–	–	0.11%	64
2014 Q1	$5.82M	Buy	32,000 +4,667	+17%	+$924K	0.1%	65
2013 Q4	$4.65M	Buy	27,333 +10,666	+64%	+$1.72M	0.08%	60
2013 Q3	$2.61M	Buy	+16,667	New	+$3.08M	0.04%	67

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Altrinsic Global Advisors's NKTR Position: Q3 2015 in Review

Altrinsic Global Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2015, closing a stake of 30,667 shares — an estimated $5.75M sold.

Altrinsic Global Advisors first reported a position in NKTR in Q3 2013 and held it in 8 quarters. The position peaked at $7.13M in Q4 2014. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

Altrinsic Global Advisors reported no remaining Nektar Therapeutics position as of Q3 2015 after selling out during the quarter.
Altrinsic Global Advisors sold 30,667 Nektar Therapeutics shares in Q3 2015, an estimated $5.75M.
Altrinsic Global Advisors first reported a position in Nektar Therapeutics in Q3 2013 and held it in 8 quarters.
Altrinsic Global Advisors's Nektar Therapeutics position peaked at $7.13M in Q4 2014.
166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Altrinsic Global Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.